<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903354</url>
  </required_header>
  <id_info>
    <org_study_id>Hypergly&amp;Infect Orth patient</org_study_id>
    <nct_id>NCT03903354</nct_id>
  </id_info>
  <brief_title>Intraoperative Hyperglycemia and Infections After Orthopedic Surgery</brief_title>
  <official_title>Relationship Between Severe Intraoperative Hyperglycemia and Infections Within 7 Days After Orthopedic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico Bilotta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative infections are a common complication. A relationship between perioperative
      severe hyperglycemia and postoperative infections has been found in patients undergoing
      craniotomy. The aim of this study is to evaluate the epidemiology of intraoperative severe
      hyperglycemia (BGC &gt;180 mg/dL; 10 mmol/L) and postoperative infections (wound, urinary and
      prosthetic joint infection) and to investigate if severe intraoperative hyperglycemia is
      associated with an higher risk of early postoperative (within the 7th postoperative days)
      infections (wound, urinary and prosthetic joint infection).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Actual">April 13, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Days</target_duration>
  <primary_outcome>
    <measure>Severe hyperglycemia and incidence of infection</measure>
    <time_frame>Follow up of the patients for 7 days postoperatively</time_frame>
    <description>Evaluate the relationship between intraoperative severe hyperglycemia and incidence of infections at 7 days follow up.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Severe Hyperglycemia</condition>
  <condition>Postoperative Infection</condition>
  <condition>Orthopedic Patients</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Incidence of infections within 7 days postoperatively</intervention_name>
    <description>Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We are enrolling orthopedic patients undergoing surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Orthopedic patients

        Exclusion Criteria:

          -  Non-orthopedic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federico Bilotta, M.D., Ph.D.</last_name>
    <phone>3393370822</phone>
    <email>bilotta@tiscali.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sapienza</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Bilotta, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Federico Bilotta</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

